Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Bausch Health (NYSE:BHC) announced that CEO Thomas J. Appio will participate at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026. Executive attendees include EVP/CFO Jean-Jacques Charhon and EVP/CMO & Head of R&D Jonathan Sadeh, M.D..
A live audio webcast will be accessible via the company's Investor Relations website at http://ir.bauschhealth.com/events-and-presentations, with a replay available after the event. Time: 3:45 p.m. PT / 6:45 p.m. ET.
Positive
- None.
Negative
- None.
News Market Reaction – BHC
On the day this news was published, BHC gained 2.64%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.1% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $75M to the company's valuation, bringing the market cap to $2.93B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peer moves are mixed, with names like HCM up 2.86% while ALVO, INDV and SUPN are modestly negative, suggesting stock-specific factors rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Debt exchange results | Neutral | -1.9% | Final results and expiration of senior secured notes exchange offers. |
| Dec 08 | Early exchange results | Neutral | -0.3% | Early participation results for exchange into new 2032 senior notes. |
| Dec 01 | China acquisition | Positive | +11.0% | Solta Medical acquisition of longtime China distributor to deepen local presence. |
| Nov 24 | Launch exchange offers | Neutral | +1.3% | Launch of offers to exchange 2028 notes for new 2032 senior secured notes. |
| Nov 18 | Conference participation | Neutral | +0.8% | Participation in Evercore healthcare conference with webcast for investors. |
Recent corporate actions around debt exchanges and a targeted acquisition generally saw modestly positive or limited share reactions, with no clear pattern of sharp divergences from news tone.
This announcement fits a pattern of steady corporate communication by Bausch Health. Recent months included multiple debt exchange initiatives culminating in issuance of $1.6 billion of new 10.00% senior secured notes due 2032, alongside refinancing steps highlighted in related 8-K filings. Strategically, the company also expanded internationally via Solta Medical’s acquisition of the Shibo group in China on December 1, 2025, which was followed by a share-price gain of 11.02%. Prior conference participation on December 2, 2025 had a modest positive reaction, making today’s JPM conference notice a continuation of that investor-relations cadence.
Market Pulse Summary
This announcement highlights Bausch Health’s participation in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, with senior leadership engaging investors via a webcast. It follows a series of balance-sheet-focused actions and a strategic acquisition in China, as seen in recent months’ news and 8-K filings. Investors may watch for any incremental commentary on debt structure, the Bausch + Lomb stake, or international growth to contextualize this ongoing investor-relations outreach.
AI-generated analysis. Not financial advice.
Jean-Jacques (JJ) Charhon, EVP, Chief Financial Officer, and Jonathan Sadeh, M.D., EVP, Chief Medical Officer and Head of R&D will also be in attendance.
Details
Date: Wednesday, January 14, 2026
Time: 3:45 p.m.
Webcast: http://ir.bauschhealth.com/events-and-presentations
A replay of the event will be available on the investor relations website following the event.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.
Forward-looking Statements
This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the
Investor Contact: | Media Contact: |
Garen Sarafian | Katie Savastano |
(877) 281-6642 (toll free) | (908) 569-3692 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-health-to-participate-in-the-44th-annual-jp-morgan-healthcare-conference-302651870.html
SOURCE Bausch Health Companies Inc.
